The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
A deep dive into BTK degraders for the treatment of CLL
William Wierda, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, takes a deep dive into the use of BTK degraders for the treatment of chronic lymphocytic leukemia (CLL). He discusses the mechanism of action, agents in development, associated toxicities, and how these agents may change the CLL treatment landscape. This interview was recorded via an online conference call with The Video Journal of Hematology and Hematological Oncology (VJHemOnc).
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
